Article: Other News To Note.

Actelion Ltd., of Basel, Switzerland, reported preliminary results from its RAPIDS-1 trial that evaluated Tracleer in treating digital ulcerations in scleroderma patients. The primary endpoint, preventing new digital ulcers, was achieved at an unspecified but statistically significant rate, Actelion said. It said it plans to begin the process for an orphan drug designation for Tracleer for digital ulcerations in scleroderma patients.

Alpharma Inc., of Fort Lee, N.J., said it would expand original plans to reach regulatory compliance after an FDA follow-up inspection of its Baltimore plant. The original inspection was last September. Alpharma estimates preliminary ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!